Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) Insider Sells $47,010.18 in Stock

Sera Prognostics, Inc. (NASDAQ:SERAGet Free Report) insider John J. Boniface sold 4,902 shares of the business’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $9.59, for a total transaction of $47,010.18. Following the sale, the insider now directly owns 134,869 shares of the company’s stock, valued at approximately $1,293,393.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Sera Prognostics Stock Down 5.4 %

Shares of SERA opened at $9.26 on Monday. Sera Prognostics, Inc. has a 52-week low of $1.52 and a 52-week high of $12.35. The stock has a market cap of $300.30 million, a PE ratio of -8.65 and a beta of 1.33. The firm’s fifty day moving average is $9.69 and its two-hundred day moving average is $6.83.

Sera Prognostics (NASDAQ:SERAGet Free Report) last posted its quarterly earnings results on Wednesday, March 20th. The company reported ($0.25) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.25). Sera Prognostics had a negative net margin of 11,843.79% and a negative return on equity of 46.35%. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.10 million. As a group, research analysts anticipate that Sera Prognostics, Inc. will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Perigon Wealth Management LLC acquired a new stake in shares of Sera Prognostics in the fourth quarter valued at approximately $509,000. Vanderbilt University purchased a new stake in Sera Prognostics in the 4th quarter valued at $284,000. Resource Consulting Group Inc. acquired a new stake in shares of Sera Prognostics in the 4th quarter worth $265,000. CWM LLC purchased a new position in shares of Sera Prognostics during the 4th quarter worth $242,000. Finally, Sanders Morris Harris LLC purchased a new stake in shares of Sera Prognostics in the first quarter valued at about $174,000. 54.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, William Blair reiterated an “outperform” rating on shares of Sera Prognostics in a research note on Friday.

View Our Latest Report on Sera Prognostics

About Sera Prognostics

(Get Free Report)

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

Featured Stories

Insider Buying and Selling by Quarter for Sera Prognostics (NASDAQ:SERA)

Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.